Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sevelamer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Sevelamer. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-000704-25 Sponsor Protocol Number: PASP01 Start Date*: 2017-02-28
    Sponsor Name:Queen Mary University of London
    Full Title: Prevention of Aortic Stenosis Pilot Trial
    Medical condition: Aortic Stenosis. It is caused by the build-up of calcium phosphate crystals on the aortic valve (aortic sclerosis). Progressive valve narrowing (stenosis) leads to symptoms (chest pain, syncope or ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004959-38 Sponsor Protocol Number: SPD405-319 Start Date*: 2007-05-17
    Sponsor Name:Shire Development Inc
    Full Title: A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal...
    Medical condition: Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003565-40 Sponsor Protocol Number: PA-CL-03 Start Date*: 2007-12-18
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease ...
    Medical condition: patients with chronic kidney disease undergoing hemodialysis hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003233-41 Sponsor Protocol Number: SVCARB00105 Start Date*: 2005-10-25
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009122 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002174-32 Sponsor Protocol Number: REN00304 Start Date*: 2005-01-13
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, randomized, parallel design study to investigate the efficacy and safety of sevelamer hydrochloride (Renagel®) compared with calcium acetate in peritoneal dialysis patients (REN00304)
    Medical condition: Peritoneal dialysis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10034660 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004052-12 Sponsor Protocol Number: CAN-NEFRO-2005-01 Start Date*: 2006-06-13
    Sponsor Name:Asociación Científica para la investigación Nefrológica (ACINEF)
    Full Title: Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica
    Medical condition: Enfermedad renal terminal (ESRD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002373-22 Sponsor Protocol Number: 2012-NIGRAM-VUMC-001 Start Date*: 2014-05-12
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: ThE SoF-Trial (SoFT) - The Effect of Sevelamer on FGF23 Trial - A clinical trial assessing the quantitative effect of phosphate binding therapy on FGF23.
    Medical condition: cardiovascular disease in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006320-20 Sponsor Protocol Number: CT.SVL.PD.10.001 Start Date*: 2012-05-17
    Sponsor Name:Synthon BV
    Full Title: A multicenter, randomized, double-blind, multiple dose, crossover study to evaluate the safety and equivalence of serum phosphate control of a new sevelamer carbonate tablet formulation in compari...
    Medical condition: Evaluation of the safety and equivalence of serum phosphate control of a sevelamer carbonate tablet formulation in comparison with Renvela® in chronic kidney disease patients on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001608-11 Sponsor Protocol Number: SPD405-310 Start Date*: 2004-11-18
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End S...
    Medical condition: Hyperphosphataemia in Patients Receiving Haemodialysis for End Stage Renal Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002329-23 Sponsor Protocol Number: SVCARB07609 Start Date*: 2013-06-20
    Sponsor Name:Genzyme Corporation and its Affiliates
    Full Title: A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate ...
    Medical condition: Treatment of hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001787-23 Sponsor Protocol Number: CSBR759A2201 Start Date*: 2008-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels i...
    Medical condition: Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) GB (Completed) FI (Completed) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001772-22 Sponsor Protocol Number: 96HCL15_0122 Start Date*: 2016-01-25
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Mesures des modifications hémodynamiques, fonctionnelles et métaboliques rénales par TEP et BOLD- IRM en lien avec la modification des apports en AGE dans l’alimentation, ou avec sevelamer. ETUDE A...
    Medical condition: Volontaires sains
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022891 - Investigations 10058910 General physical condition normal PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005416-26 Sponsor Protocol Number: ANSWER Start Date*: 2014-06-06
    Sponsor Name:Mario Negri Institute
    Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein...
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020415-36 Sponsor Protocol Number: SUS2010GOLA01 Start Date*: 2010-07-15
    Sponsor Name:Stavanger University Hospital
    Full Title: En åpen, randomisert cross over studie av fosfatbinder (sevelamer) eller aktivt vitamin D hos pasienter med kronisk nyresvikt i stadium 3b (eGFR 30-45 ml/min/1,73 m2) for evaluering av fibroblast l...
    Medical condition: Chronic renal failure, stage 3B.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003330-15 Sponsor Protocol Number: MCI-196-E10 Start Date*: 2007-01-30
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison wit...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003885-16 Sponsor Protocol Number: SVCARB00606 Start Date*: 2008-08-19
    Sponsor Name:Genzyme Europe BV
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patien...
    Medical condition: Treatment of hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004730-25 Sponsor Protocol Number: ACT 402 Start Date*: 2009-05-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) LT (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003323-37 Sponsor Protocol Number: MCI-196-E07 Start Date*: 2007-01-29
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorpora...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004673-17 Sponsor Protocol Number: PHRC IR08 - Pr. FOURNIER Start Date*: 2009-03-23
    Sponsor Name:CHU d'Amiens
    Full Title: Comparaison du nicotinamide et du sevelamer hydrochloride sur le contrôle de la phosphatémie des hémodialysés chroniques
    Medical condition: Ostéodystrophie rénale
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022011-19 Sponsor Protocol Number: PA-CL-05A Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomised Co...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.0 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:31:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA